Meeting
2019 ASCO Annual Meeting
Development and external validation of a deep learning model for predicting response to HER2-targeted neoadjuvant therapy from pretreatment breast MRI.
Authors
Manasa Vulchi
Cleveland Clinic, Cleveland, OH
Manasa Vulchi , Mohammed El Adoui , Nathaniel Braman , Paulette Turk , Maryam Etesami , Stylianos Drisis , Donna Plecha , Mohammed Benjelloun , Anant Madabhushi , Jame Abraham
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Citation
J Clin Oncol 37, 2019 (suppl; abstr 593)
DOI
10.1200/JCO.2019.37.15_suppl.593
Abstract #
593
Poster Bd #
85
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Tolerability and effectiveness of pertuzumab-containing neoadjuvant (NA) regimens vs. AC-TH for HER2-positive (+) localized breast cancer (BC).
First Author: Laura Spring
Poster
2013 ASCO Annual Meeting
Phase I/II study of neoadjuvant carboplatin, eribulin mesylate, and trastuzumab (ECH) for operable HER2 positive (HER2+) breast cancer.
First Author: Lee Steven Schwartzberg
First Author: Nicholas Patrick McAndrew
Poster
2022 ASCO Annual Meeting
DECRESCENDO: De-escalation of adjuvant chemotherapy in patients with HER2+/HR-/node-negative early breast cancer who achieve pCR after neoadjuvant taxane and subcutaneous dual anti-HER2 blockade.
First Author: Veronique Debien